MONTREAL, QUEBEC--(CCNMatthews - March 14, 2006) - From its Study Conducted in Collaboration with Helsinki University, Finland, for the Development of a Novel Prognostic Blood Test for Osteoporosis. Osta Biotechnologies Inc. (TSX VENTURE:OBI) today announced promising results of its clinical study for the development of a novel prognostic blood test for risk of osteoporosis involving a total of 234 young Finnish males. This human clinical study was conducted in collaboration with Helsinki University, Finland and shows that alterations in the human Parathyroid Hormone Related Peptide (PTHrP) gene correlate significantly with bone mass in young Finnish males.
